Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14

Abstract

Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non–small cell lung cancer (NSCLC) positive for skipping mutations of MET exon 14 (METex14). Drug‐induced interstitial lung disease (ILD) is a relatively rare, but potentially serious, side effect of TKIs administered for lung cancer treatment. Here we report a case of capmatinib‐induced ILD in a patient with NSCLC harboring a METex14 skipping mutation. Capmatinib should be immediately discontinued if ILD is suspected, and treatment with corticosteroid should be considered.

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

“…Although MET TKI-induced ILDs have been reported, 2 , 3 , 5 whether MET TKIs can be rechallenged after MET TKI-induced ILDs remains unknown. In this case, we decided to switch from capmatinib to tepotinib after capmatinib-induced ILD because she still had a chance to get a survival benefit from the MET TKIs after a series of multiple anticancer regimens.…”

<i>Mesenchymal-epithelial Transition</i> Exon 14-skipping Mutation-positive Invasive Mucinous Adenocarcinoma of the Lung: First Case Treated with Mesenchymal-epithelial Transition-tyrosine Kinase Inhibitors

“…In July and August 2022, the patient underwent a radiological re-evaluation for cancer staging using CT and 18 F fluorodeoxyglucose (FDG) positron emission tomography (PET). The IMA lesions had modestly extended into the up-per and middle lobes over the past year, with marginal lymph node enlargement observed on CT (Fig.…”

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives

“… 81 , 82 Rare cases of severe respiratory adverse events (AEs) (including pneumonitis and interstitial lung disease) have been reported with some ALK, EGFR, and MET inhibitors, which could limit the use of these therapies before surgical resection. 83 , 84 Other reported rare toxicities that may impact surgery include the following: cardiotoxicity (osimertinib), 85 , 86 bradycardia (alectinib and crizotinib), 87 , 88 thrombocytopenia (osimertinib), 89 fever (dabrafenib plus trametinib), 90 hepatotoxicity (sotorasib), 91 and CNS toxicity (lorlatinib). 92 Preliminary results from the ALK -positive cohort of the NAUTIKA1 study demonstrated that neoadjuvant alectinib was well tolerated in patients with resectable NSCLC, and to date, all patients have undergone surgery without delays or major complications.…”